晚期滤泡性淋巴瘤BR方案后早期进展与高转化风险相关
该回顾性队列研究纳入296例接受一线苯达莫司汀联合利妥昔单抗(BR)及利妥昔单抗维持治疗的晚期滤泡性淋巴瘤患者,2年无事件生存率为85%(95%CI 80-89),2年总生存率为92%(95%CI 88-95)。24个月内疾病进展(POD24)发生于13%的患者,其2年总生存率仅38%(95%CI 20-55),且76%的POD24患者存在组织学转化。
要点
- 一线BR治疗的晚期FL患者2年EFS为85%,2年OS为92%。
- POD24发生率为13%,POD24患者2年OS为38%。
- 76%的POD24患者发生组织学转化,基线LDH升高是唯一显著危险因素(P<.001)。
核心结论
- 一线BR治疗的晚期FL患者中,POD24与显著更差的总生存相关,且多数POD24患者存在组织学转化。
研究设计与样本
- 回顾性分析基于人群的队列,纳入296例接受一线BR及利妥昔单抗维持治疗的晚期滤泡性淋巴瘤患者。
主要发现
- 2年无事件生存率为85%(95%CI 80-89),2年总生存率为92%(95%CI 88-95)。
- POD24发生于13%的患者,其2年总生存率为38%(95%CI 20-55)。
- 基线乳酸脱氢酶升高是POD24的唯一显著危险因素(P<.001)。
- 76%的POD24患者存在转化性疾病。
- 与历史R-CVP队列相比,无事件生存改善且POD24风险降低,但POD24患者中转化比例更高,总体转化发生率似乎不变。
关键数值与推荐
- 2年无事件生存率85%(95%CI 80-89),2年总生存率92%(95%CI 88-95)。
- POD24发生率13%,POD24患者2年总生存率38%(95%CI 20-55)。
- 基线LDH升高与POD24显著相关(P<.001)。
- POD24患者中76%存在转化。
临床怎么用
- 一线BR治疗的晚期FL患者需关注POD24,尤其基线LDH升高者。
- POD24患者中多数存在组织学转化,识别转化生物标志物及改进管理策略对改善结局至关重要。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite widespread use of bendamustine and rituximab (BR) as frontline therapy for advanced-stage follicular lymphoma (FL), little is known about the risk of early progression or incidence of histological transformation. We performed a retrospective analysis of a population-based cohort of 296 patients with advanced-stage FL treated with frontline BR and maintenance rituximab. As previously demonstrated, outcomes with this regimen are excellent, with 2-year event-free survival estimated at 85% (95% confidence interval [95% CI], 80-89) and 2-year overall survival 92% (95% CI, 88-95). Progression of disease within 24 months (POD24) occurred in 13% of patients and was associated with a significantly inferior outcome with 2-year overall survival of 38% (95% CI, 20-55). The only significant risk factor for POD24 at baseline was elevated lactate dehydrogenase (P < .001). Importantly, the majority of POD24 patients (76%) had transformed disease. Compared with a historical cohort treated with rituximab, cyclophosphamide, vincristine, and prednisone, event-free survival has improved and the risk of POD24 has decreased, but a higher proportion of patients with POD24 harbor transformation. The overall incidence of transformation appears unchanged. The presence of occult or early transformation is the main driver of POD24 in FL patients treated with frontline BR. Identification of biomarkers and improved management strategies for transformation will be crucial to improving outcomes.
引用
- Freeman CL, Kridel R, Moccia AA, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019. PMID: 31300404. doi:10.1182/blood.2019000258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。